Literature DB >> 16596002

Successful vancomycin desensitization with a combination of rapid and slow infusion methods.

Takatoshi Kitazawa1, Yasuo Ota, Nanae Kada, Yuji Morisawa, Atsushi Yoshida, Kazuhiko Koike, Satoshi Kimura.   

Abstract

Vancomycin, an antibiotic to which methicillin-resistant Staphylococcus aureus (MRSA) is sensitive, frequently induces hypersensitivity reactions. Lowering the vancomycin infusion rate and/or premedicating with antihistamine effectively reduce hypersensitivity in most cases. However, vancomycin desensitization is sometimes the only way to ensure safe use. Two types of desensitization protocols have been reported, and these utilize different infusion intervals; rapid desensitization and slow desensitization. We herein report a case of vancomycin hypersensitivity with methicillin-resistant Staphylococcus aureus infection. A combination of the two desensitization protocols, rapid desensitization followed by slow desensitization, effectively inhibited the hypersensitivity reaction during vancomycin infusion, and methicillin-resistant Staphylococcus aureus was successfully eradicated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596002     DOI: 10.2169/internalmedicine.45.1388

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

1.  Immune-mediated reactions to vancomycin: A systematic case review and analysis.

Authors:  Jasmit S Minhas; Paige G Wickner; Aidan A Long; Aleena Banerji; Kimberly G Blumenthal
Journal:  Ann Allergy Asthma Immunol       Date:  2016-05-04       Impact factor: 6.347

2.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.

Authors:  Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2016-10-12       Impact factor: 4.084

Review 3.  Road Less Traveled: Drug Hypersensitivity to Fluoroquinolones, Vancomycin, Tetracyclines, and Macrolides.

Authors:  Linda J Zhu; Anne Y Liu; Priscilla H Wong; Anna Chen Arroyo
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-29       Impact factor: 10.817

4.  Update on the management of antibiotic allergy.

Authors:  Bernard Yu-Hor Thong
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

5.  Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.

Authors:  Mario Sánchez-Borges; Bernard Thong; Miguel Blanca; Luis Felipe Chiaverini Ensina; Sandra González-Díaz; Paul A Greenberger; Edgardo Jares; Young-Koo Jee; Luciana Kase-Tanno; David Khan; Jung-Won Park; Werner Pichler; Antonino Romano; Maria José Torres Jaén
Journal:  World Allergy Organ J       Date:  2013-10-31       Impact factor: 4.084

6.  Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient.

Authors:  Shanti Mahabir; Ren Yik Lim; Fidelma Fitzpatrick; Colm Magee; Mary Keogan
Journal:  World Allergy Organ J       Date:  2013-09-30       Impact factor: 4.084

Review 7.  Glycopeptide Hypersensitivity and Adverse Reactions.

Authors:  Vanthida Huang; Nicola A Clayton; Kimberly H Welker
Journal:  Pharmacy (Basel)       Date:  2020-04-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.